Oronsky, B., Carter, C. A., Caroen, S., Scribner, C., Oronsky, A., & Reid, T. R. (2020).  RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic". Oncoimmunology.

Oronsky, Bryan, Corey A. Carter, Scott Caroen, Curtis Scribner, Arnold Oronsky, and Tony R. Reid. " RRx-001, a First-in-class Small Molecule Inhibitor of MYC and a Downregulator of CD47, Is an "erythrophagoimmunotherapeutic"." Oncoimmunology 2020.

Oronsky, Bryan, et al. " RRx-001, a First-in-class Small Molecule Inhibitor of MYC and a Downregulator of CD47, Is an "erythrophagoimmunotherapeutic"." Oncoimmunology 2020.